Jim Simons Cns Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.19 - $292.65 $10,792 - $16.6 Million	56,800 New	56,800 $10,000
Q2 2022 Aug 12, 2022	SELL	$0.26 - $0.43 $131,698 - $217,808	-506,532 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.26 - $1.05 $93,296 - $376,773	358,832 Added 242.95%	506,532 $173,000
Q4 2021 Feb 11, 2022	BUY	$0.7 - $1.54 $103,390 - $227,458	147,700 New	147,700 $104,000
Q3 2021 Nov 12, 2021	SELL	$1.4 - $1.98 $604,952 - $855,575	-432,109 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$1.71 - $2.42 $497,013 - $703,375	-290,651 Reduced 40.21%	432,109 $847,000
Q1 2021 May 13, 2021	BUY	$1.72 - $4.18 $1.24 Million - $3.02 Million	722,760 New	722,760 $1.73 Million

100

Ticker CNSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,032,500
Market Cap $4.4M
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme....

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.